



JF

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Wright *et al.*

Serial No.: 10/770,668

Filed: 02/02/2004

Entitled: **Cell-Killing Molecules and Methods of Use
Thereof**

Group No.: 1642

Examiner: Fetterolf, B.J.

TRANSMITTAL LETTER

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.8(a)(1)(i)(A)

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop - Fee Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated 12/29/05

By

Gregory S. Mot
Gregory S. Mot

Sir or Madam:

Applicants submit the following for filing in this matter:

1. Information Disclosure Statement and Form PTO-1449, including copies of the references contained thereon, for filing in the U.S. Patent and Trademark Office.
2. Return receipt postcard.

We hereby authorize the Commissioner to charge any fee required for this filing or credit any overpayment to Deposit Account No. **08-1290**. A signed copy of this letter is enclosed for this purpose.

Dated: 12/29/05

Christine A. Lekutis

Christine A. Lekutis

Registration No.: 51,934

MEDLEN & CARROLL, LLP
101 Howard Street, Suite 350
San Francisco, California 94105
(415) 904-6500



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **Wright et al.**

Serial No.: **10/770,668**

Filed: **02/02/04**

Entitled: **Cell-Killing Molecules and Methods of Use
Thereof**

Group No.: **1642**

Examiner: **Fetterolf, B.J.**

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on **December 29, 2005**

By: _____

[Signature]
Gregory S. Mot

Sir:

The citations listed below, copies attached, may be material to the examination of the above-identified application, and are therefore submitted in compliance with the duty of disclosure defined in 37 C.F.R. §§ 1.56 and 1.97. The Examiner is requested to make these citations of official record in this application.

The following U.S. patent applications and U.S. patents are referred to in the body of the specification and not provided herein per 37 C.F.R. 1.98:

- U.S. 3,859,277 to Murakami, et al (1/7/75);
- U.S. 4,039,578 to Suami (8/2/77);
- U.S. 4,301,277 to Acton, et al (11/17/81);
- U.S. 4,314,054 to Acton, et al (2/2/82);
- U.S. 4,490,529 to Rosowsky (12/25/84);
- U.S. 4,494,547 to Myers (1/22/85);
- U.S. 4,579,827 to Sakamoto, et al (4/1/86);
- U.S. 4,585,859 to Mosher, et al (4/29/86);
- U.S. 4,639,512 to Audibert, et al (1/27/87);
- U.S. 4,681,091 to Picker, et al (7/21/87);

- U.S. 4,683,195 to Mullis, et al (7/28/87);
- U.S. 4,683,202 to Mullis (7/28/87);
- U.S. 4,713,352 to Bander, et al (12/15/87);
- U.S. 4,725,687 to Piper, et al (2/16/88);
- U.S. 4,737,579 to Hellstrom, et al (4/12/88);
- U.S. 4,753,894 to Frankel, et al (6/28/88);
- U.S. 4,797,397 to Suto, et al (1/10/89);
- U.S. 4,816,397 to Boss, et al (3/28/89);
- U.S. 4,894,364 to Greer (1/16/90);
- U.S. 4,902,791 to Roger, et al (2/20/90);
- U.S. 4,921,963 to Skov, et al (5/1/90);
- U.S. 4,927,941 to Kagiya, et al (5/22/90);
- U.S. 4,946,778 to Ladner, et al (8/7/90);
- U.S. 4,950,480 to Barber, et al (8/21/90);
- U.S. 5,004,606 to Frincke, et al (4/2/91);
- U.S. 5,100,885 to Abrams, et al (3/31/92);
- U.S. 5,147,652 to Egyud (9/15/92);
- U.S. 5,175,287 to Lee, et al (12/29/92);
- U.S. 5,194,254 to Barber, et al (3/16/93);
- U.S. 5,215,738 to Lee, et al (6/1/93);
- U.S. 5,270,163 to Gold et al (12/14/93);
- U.S. 5,270,330 to Suzuki, et al (12/14/93);
- U.S. 5,294,715 to Papadopoulou-Rosenzweig, et al (3/15/94);
- U.S. 5,304,654 to Kagiya, et al (4/19/94);
- U.S. 5,342,770 to Yamasaki (8/30/94);
- U.S. 5,342,959 to Beylin, et al (8/30/94);
- U.S. 5,442,043 to Fukuta, et al (8/15/95);
- U.S. 5,457,183 to Sessler, et al (10/10/95);
- U.S. 5,543,527 to Beylin, et al (8/6/96);
- U.S. 5,545,806 to Lonberg, et al (8/13/96);
- U.S. 5,569,825 to Lonberg, et al (10/29/96);
- U.S. 5,571,845 to Denny, et al (11/5/96);
- U.S. 5,574,142 to Meyer, et al (11/12/96);
- U.S. 5,602,142 to Papadopoulou-Rosenzweig, et al (2/11/97);
- U.S. 5,616,584 to Lee, et al (4/1/97);
- U.S. 5,624,925 to Lee, et al (4/29/97);
- U.S. 5,625,126 to Lonberg, et al (4/29/97);
- U.S. 5,641,764 to Martin, et al (6/24/97);
- U.S. 5,650,442 to Mitchell, et al (7/22/97);
- U.S. 5,736,146 to Cohen, et al (4/7/98);
- U.S. 5,760,029 to Jadhav, et al (6/2/98);
- U.S. 6,071,532 to Chaikof, et al (6/6/00);
- U.S. 6,110,687 to Nilsen (8/29/00); and
- U.S. 6,409,990 to Vera (6/25/02).

The following U.S. patents are cumulative and therefore not provided per 37 C.F.R. 1.98:

- U.S. 4,816,567 to Cabilly, et al (1989);
- U.S. 4,975,369 to Beavers, et al (1990);
- U.S. 4,978,745 to Schoemaker, et al (1990);
- U.S. 6,117,631 to Nilsen (2000);
- U.S. 6,509,460 to Beigelman, et al (2003); and
- U.S. 6,511,809 to Baez, et al (2003).

The following foreign patent applications and foreign patents are referred to in the body of the specification and are provided herein, except as noted, per 37 C.F.R. 1.98:

- JP 52089680 (1977-07-27);
- JP 53149985 (1978-12-27);
- JP 55059173 (1980-05-02);
- JP 57080396 (1982-05-19);
- EP 0 0142220 (1985-05-22);
- JP 61010511 A (1984-10-12);
- JP 61167616 A (1986-07-29);
- JP 62030768 A (1987-02-09);
- JP 62039525 A (1987-02-20);
- JP 62138427 A (1987-06-22);
- JP 63099017 A (1988-04-30);
- JP 63170375 A (1988-07-14);
- EP 0 275966 (1988-07-27);
- WO 88/06158 (1988-08-25);
- EP 0 287 317 A3 (1988-10-19);
- JP 63310873 A (1988-12-19);
- EP 0 296 321 (1988-12-28);
- JP 01139596 A (1989-06-01);
- PCT/US89/02545/WO8912690 (1989-12-28);
- EP 0185225 (1990-03-01);
- JP 02076861 A (1990-03-16);
- EP 0 434960 (1991-07-03);
- FR 2683529 (1991-12-11);
- EP 0 513 351 B1 (1992-11-19);
- JP 07149737 A (1995-06-13);
- JP 8280396 (1996-10-29);

- AU1667600 (2000-06-26);
- JP 59-219300 (1984-10-12) [abstract only];
- JP 01-110675 A (1989-04-27) [abstract only];
- JP 78 95917*;
- JP 84219300*;
- DE 267495*;
- U.S.S.R. 1261253*;
- U.S.S.R. 1336489*; and
- JP 44474*.

The following foreign patents are cumulative and therefore not provided per 37 C.F.R.

1.98:

- JP 6203767 A (1987-02-09); and
- JP 62030777 A (1987-02-09).

The following printed publications are referred to in the body of the specification and provided to the Examiner:

- Altschul et al. (1997) Gapped BLAST and PSI-BLAST: a new generation of protein database search programs, *Nucleic Acids Res.* 25(17):3389-3402;
- Arora et al. (1999) Vascular endothelial (growth factor chimeric toxin is highly active against endothelial (cells, *Cancer Res* 59:183-188;
- Bhaskar et al. (2003) E-selectin up-regulation allows for targeted drug delivery in prostate cancer, *Cancer Res* 63:6387-6394;
- Carlson et al. (1985) Antigenic characterization of human hepatocellular carcinoma. Development of in vitro and in vivo immunoassays that use monoclonal (antibodies, *J Clin Invest* 76(1):40-51;
- Chen et al. (1997) Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype, and resistance to cyclosporins. *J Biol Chem.* 1997 Feb 28;272(9):5974-82;
- Clackson et al., 1991, Making Antibody Fragments Using Phage Display Libraries *Nature*, 352:624-688;
- Dang et al. (1988) Identification of the human c-myc protein nuclear translocation signal, *Mol Cell Biol.* 8:4048-4054;
- Dang et al. (1989) Nuclear and nucleolar targeting sequences of c-erb-A, c-myb, N-myc, p53, HSP70, and HIV tat proteins, *J Biol Chem* 264:18019-18023;
- Daugherty et al. (1991) Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal (antibody directed against the CD18 component of leukocyte integrins, *Nucl. Acids Res.*, 19:2471-2476;
- Davis et al. (1998) Anti-idiotypic antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone, *Blood* 92:1184-1190
- De Kruif et al. (1996) Biosynthetically lipid-modified human scFv fragments from phage display libraries as targeting molecules for immunoliposomes, *FEBS Lett.*, 399:232-236;

* Applicant is unable to locate a hard copy of this reference at this time. If the examiner requests a copy applicant will endeavor to provide one.

- Drabick et al. (1998) Covalent polymyxin B conjugate with human immunoglobulin G as an antiendotoxin reagent, *Antimicrob. Agents Chemother.*, 42:583-588;
- Fawell et al. (1994) Tat-mediated delivery of heterologous proteins into cells, *Proc Natl Acad Sci* 91:664-668;
- Fridman et al. (2001) Cytochrome c depletion upon expression of Bcl-XS, *J Biol Chem* 276(6): 4205-10;
- Frohman et al. (1988) Rapid production of full-length cDNAs from rare transcripts: amplification using a single gene-specific oligonucleotide primer, *PNAS USA* 85:8998;
- Gilliland et al. (1980) Antibody-directed cytotoxic agents: use of monoclonal (antibody to direct the action of toxin A chains to colorectal (carcinoma cells, *Proc. Nat'l Acad. Sci. USA* 77:4539;
- Hara et al. (1997) Inhibition of interleukin 1 β converting enzyme family proteases reduces ischemic and excitotoxic neuronal (damage, *Proc Natl Acad Sci USA* 94:2007-2012;
- Hazlehurst et al., 2001, Reduction in drug-induced DNA double-strand breaks associated with β 1 integrin-mediated adhesion correlates with drug resistance in U937 cells, *Blood* 96:1897-1903;
- von Heijne (1985) The leader peptides from bacteriorhodopsin and halorhodopsin are potential (membrane-spanning amphipathic helices, *J. Mol. Biol.* 184: 99-105;
- Hellstrom et al. (1986) Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas, *Proc. Natl. Acad. Sci. USA* 83:7059-7063;
- Hood et al. (2002) Tumor regression by targeted gene delivery to the neovasculature, *Science* 296, 2404 -2407;
- Huse et al., (1989) Generation of a large combinatorial (library of the immunoglobulin repertoire in phage lambda, *Science*, 246:1275-1281
- Karaoglu et al. (1995) Functional (characterization of Ost3p. Loss of the 34-kD subunit of the *Saccharomyces cerevisiae* oligosaccharyltransferase results in biased underglycosylation of acceptor substrates, *J. Cell Biol.* 130:567-577;
- Kawakami et al. (2002) Interleukin 4 receptor on human lung cancer: a molecular target for cytotoxin therapy, *Clin Cancer Res* 8:3503-3511;
- Knoll et al. (2000) Targeted therapy of experimental (renal (cell carcinoma with a novel conjugate of monoclonal (antibody 138H11 and calicheamicin θ 1, *Cancer Res* 60:6089-6094;
- Koivunen et al. (1994) Isolation of a highly specific ligand for the α 5 β 1 integrin from a phage display library. *J. Cell Biol.*, 124: 373-380;
- Krolick et al. (1980) Selective killing of normal (or neoplastic B cells by antibodies coupled to the A chain of ricin, *Proc. Nat'l Acad. Sci. USA* 77:5419;
- Lavaissiere et al ((1996) Overexpression of human aspartyl(asparaginyl) β -hydroxylase in hepatocellular carcinoma and cholangiocarcinoma, *J Clin Invest* 98(6):1313-23;
- Lechardeur, et al. (2000) Determinants of the nuclear localization of the heterodimeric DNA fragmentation factor (ICAD/CAD), *J Cell Biol* 150: 321-334;
- Lei et al. (1987) Characterization of the *Erwinia carotovora* pelB gene and its product pectate lyase. *J. Bacteriol.* 169:4379;
- Liang et al., 1996, Parallel Synthesis and Screening of a Solid Phase Carbohydrate Library, *Science* 274:1520-1522;
- Liu et al. (1996) Eradication of large colon tumor xenografts by targeted delivery of maytansinoids, *Proc Natl Acad Sci* 93:8618-8623;

- Loeber et al., 1991, Human NAD(+)-dependent mitochondrial (malic enzyme. cDNA cloning, primary structure, and expression in Escherichia coli, J. Biol. Chem. 266:3016-3021;
- McCafferty et al., 1990, Phage antibodies: filamentous phage displaying antibody variable domains, Nature, 348:552-554;
- Ohara et al. (1989) One-Sided Polymerase Chain Reaction: The Amplification of cDNA, PNAS USA 86:5673-5677;
- Pai-Scherf et al. (1999) Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor, Clin Cancer Res 5:2311-2315;
- Pennington et al. (2001) I κ B kinase-dependent chronic activation of NF- κ B is necessary for p21^{WAF/Cip1} inhibition of differentiation-induced apoptosis of monocytes, Mol Cell Biol 21:1930-1941;
- Reed, 1997, Double identity for proteins of the Bcl-2 family, Nature 387(6635): 773-776;
- Roninson et al. (1986) Isolation of human mdr DNA sequences in multidrug-resistant KB carcinoma cells, Proc Natl Acad Sci 83:4538-4542;
- Ross et al. (2002) Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate, Cancer Res 62:2546-2553;
- Samejima et al. (1998) Transition from caspase-dependent to caspase-independent mechanisms at the onset of apoptotic execution, J Cell Biol 143:225-239;
- Shouval et al. (1982) Selecting binding and complement-mediated lysis of human hepatoma cells (PLC/PRF/5) in culture by monoclonal (antibodies to hepatitis B surface antigen, Proc Natl Acad Sci, USA 79:650-4;
- Suzuki et al. (2002) Possible existence of common internalization mechanisms among arginine-rich peptides, J Biol Chem 277:2437-2443;
- Tafani et al. (2000) Cytochrome c-dependent activation of caspase-3 by tumor necrosis factor requires induction of the mitochondrial (permeability transition, Am. J. Pathol. 156, 2111-2121;
- Tolcher et al. (1999) Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer, J Clin Oncol 17:478-484;
- Vivès et al., 1997 A Truncated HIV-1 Tat Protein Basic Domain Rapidly Translocates through the Plasma Membrane and Accumulates in the Cell Nucleus, J Biol Chem 272:16010-16017;
- Vuist et al. (1994) Lymphoma regression induced by monoclonal (anti-idiotypic antibodies correlates with their ability to induce Ig signal (transduction and is not prevented by tumor expression of high levels of bcl-2 protein, Blood 83:899-906;
- Wright et al. (1994) Purification of a 24-kD protease from apoptotic tumor cells that activates DNA fragmentation, J Exp Med. Dec 1;180(6):2113-23;
- Wright et al. (1996) Biochemical (pathways of apoptosis: nicotinamide adenine dinucleotide-deficient cells are resistant to tumor necrosis factor or ultraviolet light activation of the 24-kD apoptotic protease and DNA fragmentation. J. Exp. Med. 183: 463-471;
- Wright et al. (1997) Activation of CPP32-like proteases is not sufficient to trigger apoptosis: inhibition of apoptosis by agents that suppress activation of AP24, but not CPP32-like activity, J Exp Med. Oct 6;186(7):1107-17;
- Xu et al. (2000) Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2, Clin Cancer Res 6:3334-3341;
- Yang et al., 2001, Preparation and activity of conjugate of monoclonal (antibody Hab18

against hepatoma F(ab')(2) fragment and staphylococcal (enterotoxin A., World J Gastroenterol. 7:216-221; and

- Youle and Neville (1980) Anti-Thy 1.2 monoclonal (antibody linked to ricin is a potent cell-type-specific toxin. Proc. Nat'l Acad. Sci. U.S.A.77:5483.

The following are abstracts for references provided within the specification:

- Akamatsu et al. (1998) A single-chain immunotoxin against carcinoembryonic antigen that suppresses growth of colorectal (carcinoma cells, Clin Cancer Res., Nov;4(11):2825-32;
- Altschul, et al., 1990, Basic local (alignment search tool, J. Mol. Biol. 215:403-10;
- Balinsky et al., 1984, Enzyme activities in normal, dysplastic, and cancerous human breast tissues, J. Natl. Cancer Inst. 72:217-224;
- Bernhard et al., 1983, Guinea pig line 10 hepatocarcinoma model: characterization of monoclonal (antibody and in vivo effect of unconjugated antibody and antibody conjugated to diphtheria toxin A chain, Cancer Res 43:4420-4428;
- Brody et al, 1999, The use of aptamers in large arrays for molecular diagnostics. Mol Diagn December;4(4):381-8;
- Byers et al., 1989, Phase I study of monoclonal (antibody-ricin A chain immunotoxin XomaZyme-791 in patients with metastatic colon cancer, Cancer Res 49:6153-6160;
- Carloni et al., 1998, Knockout of alpha6 beta1-integrin expression reverses the transformed phenotype of hepatocarcinoma cells, Gastroenterology, Aug;115(2):433-42;
- Chan et al, 2001, A humanized monoclonal (antibody constructed from intronless expression vectors targets human hepatocellular carcinoma cells, Biochem. Biophys. Res. Commun. 284:157-167;
- Chang et al, 1989, Serological (analysis and biochemical (characterization of monoclonal (antibodies defining antigens of human hepatocellular carcinoma, Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi. 1989 Feb;22(1):1-20;
- Chou, 1996, Nonidentity of the cDNA sequence of human breast cancer cell malic enzyme to that from the normal (human cell, J. Protein Chem. 15:273-279;
- Chou et al., 1997, Expression of P-glycoprotein and p53 in advanced hepatocellular carcinoma treated by single agent chemotherapy: clinical (correlation, J Gastroenterol Hepatol 12:569-575;
- Chou et al., 1999, Solution structure of BID, an intracellular amplifier of apoptotic signaling, Cell, 96: 615-624;
- Coultas et al., 2003, The role of the Bcl-2 protein family in cancer, Semin Cancer Biol 13:115-123;
- Davol et al., 1999, Targeting human prostatic carcinoma through basic fibroblast growth factor receptors in an animal (model: characterizing and circumventing mechanisms of tumor resistance, Prostate 40:178-191;
- Derossi et al., 1998, Trojan peptides: the penetratin system for intracellular delivery, Trends Cell Biol 8:84-87;
- Di Lazzaro et al., 1994, Immunotoxins to the HER-2 oncogene product: functional (and ultrastructural (analysis of their cytotoxic activity, Cancer Immunol Immunother 39:318-324;
- Ding et al., 1995, Synthesis and biological (activity of oligosaccharide libraries. Adv. Expt. Med. Biol. 376:261-269;
- Drebin et al., 1988, Monoclonal (antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo, Oncogene 2:387-394;

- Dunk et al, 1987, In vitro and in vivo tumour localisation with a monoclonal (antibody directed against a membrane antigen on the human hepatocellular carcinoma cell line PLC/PRF/5 J Hepatol 4(1):52-61;
- Ecker and Crook, 1995, Combinatorial (drug discovery: which methods will produce the greatest value, Biotechnology (N Y), Apr;13(4):351-60;
- Elliot et al., 1997, Intercellular trafficking and protein delivery by a herpesvirus structural (protein. Cell 88:223-233;
- Enari et al., 1998, A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor, ICAD, Proc. Natl. Acad. Sci. 95:9123-9128;
- Ewend et al., 1996, Local (delivery of chemotherapy and concurrent external (beam radiotherapy prolongs survival (in metastatic brain tumor models, Cancer Research 56(22):5217-5223;
- Faouzi et al., 1999, Myofibroblasts are responsible for collagen synthesis in the stroma of human hepatocellular carcinoma: an *in vivo* and *in vitro* study, J Hepatol 30:275-284;
- Fitzgerald et al., 1989, Targeted toxin therapy for the treatment of cancer, J. Nat'l Cancer Inst. 81:1455;
- Friede et al., 1994, Selective induction of protection against influenza virus infection in mice by a lipid-peptide conjugate delivered in liposomes, Vaccine, 12:791-797;
- Fuhrer et al., 1991, Characterization of a membrane-associated glycoprotein (gp43) on human hepatocellular carcinomas by a monoclonal (antibody, Cancer Res. 51:2158-2163;
- Fukuda et al., 1988, A monoclonal (antibody to the carbohydrate chain on human hepatocellular carcinoma-associated antigen which suppressed tumor growth in nude mice, Cancer Immunol Immunother 27(1):26-32;
- Gao et al., 2003, De novo identification of tumor-specific internalizing human antibody-receptor pairs by phage-display methods, J Immunol Methods 274:185-197;
- Ghetie et al., 1997, Immunotoxins for the treatment of B-cell lymphomas, Mol Med 3:420-427;
- Gho et al., 1999, Luteinizing hormone releasing hormone-RNase A conjugates specifically inhibit the proliferation of LHRH-receptor-positive human prostate and breast tumor cells, Mol Cells 9:31-36;
- Giantonio et al., 1997, Superantigen-based immunotherapy: a phase I trial (of PNU-214565, a monoclonal (antibody-staphylococcal (enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal (cancer, J Clin Oncol 15:1994-2007;
- Gilbert and Knox, 1997, Influence of Bcl-2 overexpression on Na⁺/K⁺-ATPase pump activity: correlation with radiation-induced programmed cell death. J Cell Physiol. Jun;171(3):299-304;
- Goldstein et al., 1988, Expression of a multidrug resistance gene in human cancers, J Natl Cancer Inst 81:116-124;
- Hiraiwa et al. (1990) Accumulation of highly acidic sulfated glycosphingolipids in human hepatocellular carcinoma defined by a series of monoclonal (antibodies, Cancer Res 50(10):2917-28;
- Hiraiwa et al. (1990) Gangliosides and sialoglycoproteins carrying a rare blood group antigen determinant, Cad, associated with human cancers as detected by specific monoclonal (antibodies, Cancer Res 50(17):5497-503;
- Hu et al, 1999, Cloning and sequencing of variable region genes of HAb25 McAb against hepatocellular carcinoma, Zhonghua Gan Zang Bing Za Zhi.7(2):101-3. [Article in Chinese];
- Hu et al., 1986, Monoclonal (antibodies against antigens expressed on human

hepatocellular carcinoma cells. *Hepatology* 6(6):1396-402;

- Huang, 2000, Bcl-2 family proteins as targets for anticancer drug design, *Oncogene* 19(56): 6627-6631;
- Hwang et al., 1984, Selective antitumor effect on L10 hepatocarcinoma cells of a potent immunoconjugate composed of the A chain of abrin and a monoclonal (antibody to a hepatoma-associated antigen, *Cancer Res* 44:4578-4586;
- Jaattela et al., 1999, Minireview Escaping cell death: Survival (proteins in cancer, *Exp Cell Res* 248:30-43;
- Jaskiewicz et al., 1993, Differential (expression of extracellular matrix proteins and integrins in hepatocellular carcinoma and chronic liver disease, *Anticancer Res* 13:2229-2238;
- Jones et al., 1986, Replacing the complementarity-determining regions in a human antibody with those from a mouse *Nature*, 321:522;
- Joshi et al., 2002, IL-4 receptors on human medulloblastoma tumours serve as a sensitive target for a circular permuted IL-4-Pseudomonas exotoxin fusion protein, *Br J Cancer* 86:285-291;
- Kamps et al., 1996, Preparation and characterization of conjugates of (modified) human serum albumin and liposomes: drug carriers with an intrinsic anti-HIV activity, *Biochim. Biophys. Acta*, 1278:183-190;
- Kawahara et al., 1996 Enhanced coexpression of thioredoxin and high mobility group protein 1 genes in human hepatocellular carcinoma and the possible association with decreased sensitivity to cisplatin, *Cancer Res.* Dec 1;56(23):5330-3;
- Kawai and Hosaki, 1990, Clinical (usefulness of malate dehydrogenase and its mitochondrial (isoenzyme in comparison with aspartate aminotransferase and its mitochondrial (isoenzyme in sera of patients with liver disease, *Clin. Biochem.* 23:327-334;
- Kuwata et al, 1998, Antibody dependent cell-mediated cytotoxicity using hepatocellular carcinoma reactive monoclonal (antibody, *J Gastroenterol Hepatol* Feb;13(2):137-44;
- Kumagai et al., 1992, A new tumor-associated antigen useful for serodiagnosis of hepatocellular carcinoma, defined by monoclonal (antibody KM-2, *Cancer Res* 52(18):4987-94;
- Lee et. al., 1999, Prolonged circulating lives of single-chain Fv proteins conjugated with polyethylene glycol: a comparison of conjugation chemistries and compounds, *Bioconjug Chem* 10:973-81;
- Li et al., 1998, Cleavage of BID by caspase 8 mediates the mitochondrial (damage in the Fas pathway of apoptosis, *Cell*, 94: 491-501;
- Lindenboim et al., 2000. Bcl-xS and Bax induce different apoptotic pathways in PC12 cells, *Oncogen* 19(14): 1783-1793;
- Liu et al., 2001, Inhibition of the growth of hepatoma and hepatic metastasis by pingyangmycin conjugated with Fab' fragment of monoclonal (antibody, *Zhonghua Yi Xue Za Zhi* 81:201-201;
- Loeber et al., 1994, Purification, cDNA cloning and heterologous expression of the human mitochondrial (NADP(+)-dependent malic enzyme, *Biochem. J.* 304:687-692;
- Liu et al., 1996, Eradication of large colon tumor xenografts by targeted delivery of maytansinoids, *Proc Natl Acad Sci* 93:8618-8623;
- Loh et al. 1989, Polymerase chain reaction with single-sided specificity: analysis of T cell receptor delta chain, *Science* 243:217-220;
- Luo et al., 1998, Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors, *Cell*, 94: 481-490;

- Markham et al., 1986, Primary hepatocellular carcinoma localised by a radiolabelled monoclonal (antibody, J Hepatol 2(1):25-31;
- Marshall et al., 1997, A biopolymer by any other name would bind as well: a comparison of the ligand-binding pockets of nucleic acids and proteins, Structure, 5: 729-734;
- McDonnell et al., 1999, Solution structure of the proapoptotic molecule BID: a structural (basis for apoptotic agonists and antagonists, Cell, 96:625-634;
- Miura et al., 1993, Induction of apoptosis in fibroblasts by IL-1 beta-converting enzyme, a mammalian homolog of the *C. elegans* cell death gene ced-3, Cell 75:653;
- Moradpour et al., 1995, Specific targeting of human hepatocellular carcinoma cells by immunoliposomes in vitro, Hepatology 22(5):1527-37;
- Morris et al., 2001, A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nature Biotech 19:1173-1176;
- Motte et al. (1989) Characterization of a malignant phenotype-associated cell surface glycoprotein common to various human tumor cells and preferentially expressed on adenocarcinoma of the lung, Cancer Res 49(6): 1349-56;
- Muchi and Yamamoto, 1983, Y Studies on mitochondrial (and cytoplasmic malate dehydrogenase in childhood myelodysplastic syndrome, Blood 62:808-814;
- Murray et al, 1993, The expression of cytochrome P-450, epoxide hydrolase, and glutathione S-transferase in hepatocellular carcinoma, Cancer 71:36-43;
- Myers and Miller, 1988, Optimal (alignments in linear space, CABIOS, 4:11-17;
- Ng et al., 2000, Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response, Am J Clin Pathol 113:355-363;
- Nishimura et al., 1987, Recombinant human-mouse chimeric monoclonal (antibody specific for common acute lymphocytic leukemia antigen. Cancer Res. 1987 Feb 15;47(4):999-1005;
- Norman et al., 1993, Consensus statement regarding OKT3-induced cytokine-release syndrome and human antimouse antibodies, Transplant Proc., 25, suppl. 1:89-93;
- Ohzu et al, 1990, Multiplicity of newly established monoclonal (antibodies against hepatocellular carcinomas, J Gastroenterol Hepatol 5(6):601-7;
- Ozturk et al, 1989, Identification and characterization of a Mr 50,000 adrenal (protein in human hepatocellular carcinoma, Cancer Res. 49(23): 6764-73;
- Padlan, 1991, A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties, Molec. Immunol., 28:489;
- Padlan, 1994, Anatomy of the antibody molecule, Molec. Immun., 31(3):169-217;
- Pai et al., 1996, Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin, Nat Med 2:350-353;
- Papsidero, 1985, Recent progress in the immunological (monitoring of carcinomas using monoclonal (antibodies, Semin. Surg. Oncol. 1(4):171-81;
- Park et al., 1994, MDR1 gene expression: Its effect on drug resistance to doxorubicin in human hepatocellular carcinoma cell lines, J Natl Cancer Inst 86:700-705;
- Patriarca et al., 1993, Patterns of integrin common chain beta 1 and collagen IV immunoreactivity in hepatocellular carcinoma. Correlations with tumour growth rate, grade and size, J Pathol 171:5-11;
- Penco et al., 2001, Identification of an import signal (for, and the nuclear localization of, human lactoferrin, Biotechnol Appl Biochem 34:151-159;
- Reff et al., 2001, A review of modifications to recombinant antibodies: attempt to

increase efficacy in oncology applications, *Crit Rev Oncol/Hematol* 40:25-35;

- Seon et al., 1997, Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial (cells of tumor vasculature with antihuman endoglin immunotoxin. *Clin Cancer Res* 3:1031-1044;
- Shahinian et al., 1995, A novel strategy affords high-yield coupling of antibody Fab' fragments to liposomes, *Biochim. Biophys. Acta*, 1239:157-167;
- Shao, 1986, Action of monoclonal (antibody against a hepatocellular carcinoma cell line (PLC/PRF/5), *Zhonghua Zhong Liu Za Zhi* 8(4):259-61 [Article in Chinese];
- Shen et al., 1991, Human hepatocellular carcinoma cell lines exhibit multidrug resistance unrelated to MRD1 gene expression, *J Cell Sci* 98:317-322;
- Shimizu et al., 1997, Camptothecin-induced apoptosis in p53-null human leukemia HL60 cells and their isolated nuclei: effects of the protease inhibitors Z-VAD-fmk and dichloroisocoumarin suggest an involvement of both caspases and serine proteases, *Leukemia* 11:1238-1244;
- Shinohara et al., 2000, Site-specific expression of transferrin receptor by human colon cancer cells directly correlates with eradication by antitransferrin recombinant immunotoxin, *Int J Oncol* 17:643-651;
- Shouval (et al., 1985, Human hepatoma-associated cell surface antigen: identification and characterization by means of monoclonal (antibodies, *Hepatology* 5(3):347-56;
- Siegall et al., 1994, In vitro and in vivo characterization of BR96 sFv-PE40. A single-chain immunotoxin fusion protein that cures human breast carcinoma xenografts in athymic mice and rats, *J Immunol* 152:2377-2384;
- Sjogren et al., 1997, Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats, *Cancer Res* 57:4530-4536;
- Song et al., 1998, Enhanced radioimmunotherapeutic efficacy of a monoclonal (antibody cocktail against SMMC-7721 human hepatocellular carcinoma, *Cell Res.* 8:241-247;
- Sordet et al., 1999, Selective inhibition of apoptosis by TPA-induced differentiation of U937 leukemic cells, *Cell Death Differ* 6:351-361;
- Stein et al., 1991, A new murine monoclonal (antibody against human hepatoma, *Hybridoma* 10:255-267;
- Stemmer et al., 1995, Single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides, *Gene* 16:49-53;
- Stennicke and Salvesen, 1999, Caspases: preparation and characterization, *Methods.* Apr;17(4):313-9;
- Takahashi et al, 1989, In vivo expression of two novel tumor associated antigens and their use in immunolocalization of human hepatocellular carcinoma, *Hepatology* 9(4):625-34;
- Takahashi et al., 1988, In vivo localization of human colon adenocarcinoma by monoclonal (antibody binding to a highly expressed cell surface antigen, *Cancer Res* 48(22):6573-9;
- Takeuchi et al., 1999, Interferon-alpha modulates resistance to cisplatin in three human hepatoma cell lines, *J Gastroenterol* 34:351-358;
- Tan, 1990, Production of monoclonal (antibodies against human hepatocellular carcinoma by immunisation with a cell membrane preparation, *Ann Acad. Med. Singapore* 19:147-151;
- Tanaka et al., 1996, Molecular cloning and mapping of a human cDNA for cytosolic

malate dehydrogenase (MDH1) Genomics 32:128-130;

- Tannock, 1996, Treatment of cancer with radiation and drugs, Journal (of Clinical Oncology 14(12):3156-3174;
- Tishler et al., 1992, Taxol: a novel radiation sensitizer, Int J Radiation Oncology and Biological (Physics 22(3):613-617;
- Torbenson et al., 2002, Hepatocellular carcinomas show abnormal (expression of fibronectin protein, Mod Pathol 15:826-830;
- Tsung et al, 1980, Derivation and characterization of a monoclonal (hybridoma antibody specific for human alpha-fetoprotein. J Immunol Methods 39(4):363-8;
- Venook et al., 2000, Hepatocellular carcinoma, Curr Treat Options Oncol. Dec;1(5):407-15;
- Verheul et al., 1995, Monopalmitic acid-peptide conjugates induce cytotoxic T cell responses against malarial (epitopes: importance of spacer amino acids. J. Immunol. Methods, 182:219-226;
- Verhoeyen et al., 1988, Reshaping human antibodies: Grafting an antilysozyme activity Science, 239:1534-1536;
- Vitetta et al., 1987, Redesigning nature's poisons to create anti-tumor reagents, Science 238:1098;
- Wagenknecht, K. et al. (1988) [Malate dehydrogenase isoenzymes in myocardial (infarction) Kardiologiiia 28:55-57 [Article in Russian];
- Wang et al, 1991, Trichosanthin-monoclonal (antibody conjugate specifically cytotoxic to human hepatoma cells in vitro, Cancer Research 51:3353-3355;
- Wang et al., 1996, BID: a novel BH3 domain-only death agonist, Genes Dev., 10: 2859-2869;
- Wei et al., 2001, Proapoptotic BAX and BAK: a requisite gateway to mitochondrial (dysfunction and death, Science 292(5517): 624-626;
- Weidmann et al, 1987, Human hepatocellular carcinoma: cross-reactive and idiotypic antigens associated with malignant transformation of epithelial (cells, Hepatology 7(3):543-50;
- Wisniewska and Lukasiuk, 1985, [Malate dehydrogenase and its isoenzymes in the peripheral (blood leukocytes in progressive muscular dystrophy of the Duchenne type] Neurol. Neurochir. Pol. 19:318-322) [Article in Polish];
- Wright et al., 1992, Selection of tumor cell variants for resistance to tumor necrosis factor also induces a form of pleiotropic drug resistance, Cancer Immunol Immunother 34:399-406;
- Wright et al. (1998) Bcl-2-mediated resistance to apoptosis is associated with glutathione-induced inhibition of AP24 activation of nuclear DNA fragmentation, Cancer Res. 1998 Dec 1;58(23):5570-6;
- Xie et al., 1998, Characterization of a novel monoclonal (antibody raised against human hepatocellular carcinoma, Hybridoma 17:437-444;
- Yang et al., 1994, Sequence of light chain variable region gene of a monoclonal (antibody to human hepatocarcinoma, Zhonghua Zhong Liu Za Zhi. Jul;16(4):263-5 [Article in Chinese];
- Yang et al., 1995, Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death, Cell 80(2):285-291;
- Yao et al., 2001, Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal (antibody, J Nucl Med 42:1538-1544;
- Yoon et al., 2000, Targeting a recombinant adenovirus vector to HCC cells using a bifunctional (Fab-antibody conjugate, Biochem Biophys Res Commun 272(2):497-504;

- York et al., 1996, The structures of arabinoxyloglucans produced by solanaceous plants. Carbohydr Res. May 14;285:99-128;
- Zeng et al., 1993, Radioimmunotherapy for unresectable hepatocellular carcinoma using ¹³¹I-Hepama-1 mAb: preliminary results, J Cancer Res Clin Oncol 119:257-7;
- Zeng et al., 1994, Human anti-(murine Ig) antibody responses in patients with hepatocellular carcinoma receiving intrahepatic arterial (¹³¹I-labeled Hepama-1 mAb. Preliminary results and discussion. Cancer Immunol Immunother 39:332-336;
- Zeng et al., 1998, Improved long-term survival (for unresectable hepatocellular carcinoma (HCC) with a combination of surgery and intrahepatic arterial (infusion of ¹³¹I-anti-HCC mAb. Phase I/II clinical (trials, J Cancer Res Clin Oncol 124:275-280; and
- Zhang, et al., 2002, Beta 1-integrin protects hepatoma cells from chemotherapy induced apoptosis via a mitogen-activated protein kinase dependent pathway. Cancer 95:896-906.

Applicant is unable to locate a hard copy of the following references at this time. If the examiner request a copy applicant will try to obtain it.

- Allum et al., 1986, Monoclonal (antibodies in the diagnosis and treatment of malignant conditions, Surg Annu;18:41-64;
- Blondelle et al., 1995, Soluble combinatorial (libraries of organic, peptidomimetic and peptide diversities, Trends Anal. Chem. 14:83-92;
- Carlsson et al, 1989, Monoclonal (antibodies into the '90s: The all purpose tool, Bio/Technology, 7:567-573;
- Frohman and Martin, 1989, Rapid amplification of cDNA ends using nested primers, Techniques 1:165;
- Ghetie et al., 1997, Immunotoxins for the treatment of B-cell lymphomas, Mol Med 3:420-427;
- Gordon et al., 1994, Applications of combinatorial (technologies to drug discovery. 2. Combinatorial (organic synthesis, library screening strategies, and future directions, J. Med. Chem. 37:1385-1401;
- Houghton et al., 1986, Monoclonal (antibodies: potential (applications to the treatment of cancer, Semin. Oncol., 13(2):165-79;
- Jain et al., 1994, Barriers to drug delivery in solid tumors, Sci Am 279:58-65;
- Kabat et al., Sequences of Proteins of Immunological (Interest, NIH Pub. No. 91-3242 (5th ed., 1991) (U.S. Dept. Health & Human Services, Bethesda, Md.) ;
- Kabat et al., 1987, Sequences of Proteins of Immunological (Interest, 4th Ed. (U.S. Dept. Health and Human Services, Bethesda, Md.) ;
- Kahan et al., 1999, Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238, Int J Cancer 82:592-598;
- Köhler and Milstein, 1975, Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, 256:495-497;
- Kozbor and Roder, 1983, The production of monoclonal (antibodies from human lymphocytes, Immunol. Today, 4:72;
- Lerner, 1984, Antibodies of predetermined specificity in biology and medicine, Adv. Immunol, 36:1;
- Myers and Miller, 1988, Optimal (alignments in linear space, CABIOS, 4:11-17;


- Norman et al., 1993, Consensus statement regarding OKT3-induced cytokine-release syndrome and human antimouse antibodies, Transplant Proc., 25, suppl. 1:89-93;
- Ruoslahti et al., 1994, Anchorage dependence, integrins, and apoptosis, Cell 77:477-478;
- Schlom and Weeks, 1985, Potential (clinical utility of monoclonal (antibodies in the management of human carcinomas. Important Adv. Oncol., 170-92;
- Williamson and Corkey, 1969, Assays of intermediates of the citric acid cycle and related compounds by fluorimetric enzyme methods. Methods Enzymol., 80, 324-332;
- Xie et al, 1985, Two mouse hybridomas secreting monoclonal (antibodies against human liver carcinoma and their antibody specificity, Shi Yan Sheng Wu Xue Bao 18(2):263-70; and
- Xie et al., 2003, Characterization and mutagenesis of a single-chain Fv (scFv95) recognizing human hepatocellular carcinoma (HCC) cells, Submitted for publication;
- Cole et al., 1985, The ebv-hybridoma technique and its application to human lung cancer, in Monoclonal (Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96;
- Goodman and Gilman's, 1996, Pharmaceutical (Basis of Therapeutics ninth edition, Eds. Hardman et al;
- Pitot, 1978, in "Fundamentals of Oncology," Marcel Dekker (Ed.), New York pp 15-28;
- Griffin et al., 1988, IMMUNOTOXINS, p 433, Boston/Dordrecht/Lancaster, Kluwer Academic Publishers; and
- Watanabe, in Cloning and Sequence" edited by Masahiro Sugiura, 1989, published by Nosonbunkasha Co., Ltd., Tokyo, 48 -49.

The following are general (references listed within the specification and not provided:

- Ausubel et al., 1993, in Current Protocols in Molecular Biology, John Wiley & Sons, New York;
- Ausubel et al, ed., 2000, Current Protocols in Molecular Biology, John Wiley & Sons, New York; and
- Sambrook et al., 2001, "Molecular Cloning: A Laboratory Manual" Cold Spring Harbor Press, 3rd Edition.

This Information Disclosure Statement under 37 C.F.R. §§ 1.56 and 1.97 is not to be construed as a representation that a search has been made, that additional (information material (to the examination of this application does not exist, or that any one or more of these citations constitutes prior art.

Dated: 12/29/05



Christine A. Lekutis
Registration No.: 51,934
MEDLEN & CARROLL, LLP
101 Howard Street, Suite 305
San Francisco, California 94105
415/904-6500

FORM PTO-1449 U.S. Department of Commerce
(Modified) Patent and Trademark Office

Attorney Docket No.: ABSALUS-08602

Serial No.: 10/770,668


INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use Several Sheets If Necessary)

(37 CFR §1.98(b))

Applicant: Wright, et al.

Filing Date: 2/2/2004

Group Art Unit: 1642



U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date
	1.	3,859,277	1/7/75	Murakami, et al.	540	527	12/29/72
	2.	4,039,578	8/2/77	Suami	564	33	3/ 8/76
	3.	4,301,277	11/17/81	Acton, et al.	536	6.4	10/20/80
	4.	4,314,054	2/2/82	Acton, et al.	536	6.4	3/23/81
	5.	4,490,529	12/25/84	Rosowsky	544	260	9/6/83
	6.	4,494,547	1/22/85	Myers	604	20	3/30/81
	7.	4,579,827	4/1/86	Sakamoto, et al.	435	7.23	3/11/83
	8.	4,585,859	4/29/86	Mosher, et al.	536	6.4	4/ 9/84
	9.	4,639,512	1/27/87	Audibert, et al.	530	313	3/11/83
	10.	4,681,091	7/21/87	Picker, et al.	128	897	11/27/85
	11.	4,683,195	7/28/87	Mullis, et al.	435	6	2/7/86
	12.	4,683,202	7/28/87	Mullis	435	91	10/25/85
	13.	4,713,352	12/15/87	Bander, et al.	435	7.23	5/4/84
	14.	4,725,687	2/16/88	Piper, et al.	544	279	4/28/86
	15.	4,737,579	4/12/88	Hellstrom, et al.	530	388.85	7/23/86
	16.	4,753,894	6/28/88	Frankel, et al.	435	7.23	1/11/85
	17.	4,797,397	1/10/89	Suto, et al.	514	215	7/31/87
	18.	4,816,397	3/28/89	Boss, et al.	435	69.6	11/14/84
	19.	4,894,364	1/16/90	Greer	514	49	6/24/85
	20.	4,902,791	2/20/90	Roger, et al.	536	17.7	3/14/88
	21.	4,921,963	5/1/90	Skov, et al.	548	101	4/13/87
	22.	4,927,941	5/22/90	Kagiya, et al.	548	264.8	6/9/88
	23.	4,946,778	8/7/90	Ladner, et al.	435	69.6	1/19/89
	24.	4,950,480	8/21/90	Barber, et al.	424	178.1	5/5/87
	25.	5,004,606	4/2/91	Frincke, et al.	424	178.1	9/24/86
	26.	5,100,885	3/31/92	Abrams, et al.	514	184	8/1/89
	27.	5,147,652	9/15/92	Egyud	424	450	7/3/90
	28.	5,175,287	12/29/92	Lee, et al.	544	183	9/18/ 89
	29.	5,194,254	3/16/93	Barber, et al.	424	178.1	10/13/ 89
	30.	5,215,738	6/1/93	Lee, et al.	514	352	6/1/ 90
	31.	5,270,163	12/14/93	Gold, et al.	435	6	8/1792
	32.	5,270,330	12/14/93	Suzuki, et al.	514	398	7/24/92
	33.	5,294,715	3/15/94	Papadopoulou-Rosenzweig, et al.	546	106	2/1/ 91
	34.	5,304,654	4/19/94	Kagiya, et al.	548	327.5	9/9 91
	35.	5,342,770	8/30/94	Yamasaki	435	178	5/11/93

Examiner:

Date Considered:

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce (Modified) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR §1.98(b))	Attorney Docket No.: ABSALUS-08602	Serial No.: 10/770,668
	Applicant: Wright, et al.	
	Filing Date: 2/2/2004	Group Art Unit: 1642

36.	5,342,959	8/30/94	Beylin, et al.	548	327.5	8/ 5/93
37.	5,442,043	8/15/95	Fukuta, et al.	530	303	11/29/93
38.	5,457,183	10/10/95	Sessler, et al.	534	11	10/12/93
39.	5,543,527	8/6/96	Beylin, et al.	548	110	5/18/95
40.	5,545,806	8/13/96	Lonberg, et al.	800	6	12/16/92
41.	5,569,825	10/29/96	Lonberg, et al.	800	18	12/17/91
42.	5,571,845	11/5/96	Denny, et al.	514	619	5/26/94
43.	5,574,142	11/12/96	Meyer, et al.	536	23.1	12/15/92
44.	5,602,142	2/11/97	Papadopoulou-Rosenzweig, et al.	514	290	12/21/94
45.	5,616,584	4/1/97	Lee, et al.	514	243	1/26/95
46.	5,624,925	4/29/97	Lee, et al.	514	243	1/26/95
47.	5,625,126	4/29/97	Lonberg, et al.	800	18	12/7/94
48.	5,641,764	6/24/97	Martin, et al.	514	80	5/15/95
49.	5,650,442	7/22/97	Mitchell, et al.	514	611	10/7/94
50.	5,736,146	4/7/98	Cohen, et al.	424	197.11	2/22/95
51.	5,760,029	6/2/98	Jadhav, et al.	514	210.16	3/13/97
52.	6,071,532	6/6/00	Chaikof, et al.	424	450	10/15/96
53.	6,110,687	8/29/00	Nilsen	435	6	6/18/99
54.	6,409,990	6/25/02	Vera	424	9.35	5/12/00

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		Document Number	Publication Date	Country / Patent Office	Class	Subclass	Translation	
							Yes	No
	55.	52089680	1977-07-27	JP	-			
	56.	53149985	1978-12-27	JP				
	57.	55059173	1980-05-02	JP				
	58.	57080396	1982-05-19	JP				
	59.	0142220	1985-05-22	EP	-			
	60.	61010511 A	1986-01-18	JP				
	61.	61167616 A	1986-07-29	JP				
	62.	62030768 A	1987-02-09	JP				
	63.	62039525 A	1987-02-20	JP				
	64.	62138427 A	1987-06-22	JP				
	65.	63099017 A	1988-04-30	JP				
	66.	63170375 A	1988-07-14	JP				
	67.	275966	1988-07-27	EP				
	68.	8806158	1988-08-25	WO				
	69.	0 287 317 A3	1988-10-19	EP				

Examiner:	Date Considered:
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. Department of Commerce (Modified) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR §1.98(b))	Attorney Docket No.: ABSALUS-08602	Serial No.: 10/770,668
	Applicant: Wright, et al.	
	Filing Date: 2/2/2004	Group Art Unit: 1642

70.	63310873 A	1988-12-19	JP				
71.	01139596 A	1989-06-01	JP				
72.	8912690	1989-12-28	WO				
73.	0185225	1990-03-01	EP				
74.	02076861 A	1990-03-16	JP				
75.	0434960	1991-07-03	EP				
76.	2683529	1991-12-11	FR				
77.	0296321	1992-09-23	EP				
78.	0 513 351 B1	1992-11-19	EP				
79.	07149737 A	1995-06-13	JP				
80.	8280396	1996-10-29	JP				
81.	1667600	2000-06-26	AU				
82.	59-219300	1984-10-12	JP [abstract only]				
83.	01-110675 A	1989-04-27	JP [abstract only]				

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

84.	Altschul et al. (1997) Gapped BLAST and PSI-BLAST: a new generation of protein database search programs, Nucleic Acids Res. 25(17):3389-3402
85.	Arora et al. (1999) Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells, Cancer Res 59:183-188
86.	Bhaskar et al. (2003) E-selectin up-regulation allows for targeted drug delivery in prostate cancer, Cancer Res 63:6387-6394
87.	Carlson et al. (1985) Antigenic characterization of human hepatocellular carcinoma. Development of in vitro and in vivo immunoassays that use monoclonal antibodies, J Clin Invest 76(1):40-51
88.	Chen et al. (1997) Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype, and resistance to cyclosporins. J Biol Chem. 1997 Feb 28;272(9):5974-82
89.	Clackson et al., 1991, Making Antibody Fragments Using Phage Display Libraries Nature, 352:624-688
90.	Dang et al. (1988) Identification of the human c-myc protein nuclear translocation signal, Mol Cell Biol. 8:4048-4054
91.	Dang et al. (1989) Nuclear and nucleolar targeting sequences of c-erb-A, c-myc, N-myc, p53, HSP70, and HIV tat proteins, J Biol Chem 264:18019-18023
92.	Daugherty et al. (1991) Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins, Nucl. Acids Res., 19:2471-2476
93.	Davis et al. (1998) Anti-idiotypic antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone, Blood 92:1184-1190
94.	De Kruif et al. (1996) Biosynthetically lipid-modified human scFv fragments from phage display libraries as targeting molecules for immunoliposomes, FEBS Lett., 399:232-236
95.	Drabick et al. (1998) Covalent polymyxin B conjugate with human immunoglobulin G as an antiendotoxin reagent, Antimicrob. Agents Chemother., 42:583-588

Examiner:	Date Considered:
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. Department of Commerce (Modified) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR §1.98(b))	Attorney Docket No.: ABSALUS-08602	Serial No.: 10/770,668
	Applicant: Wright, et al.	
	Filing Date: 2/2/2004	Group Art Unit: 1642

96.	Fawell et al. (1994) Tat-mediated delivery of heterologous proteins into cells, Proc Natl Acad Sci 91:664-668
97.	Fridman et al. (2001) Cytochrome c depletion upon expression of Bcl-XS, J Biol Chem 276(6): 4205-10
98.	Frohman et al. (1988) Rapid production of full-length cDNAs from rare transcripts: amplification using a single gene-specific oligonucleotide primer, PNAS USA 85:8998
99.	Gilliland et al. (1980) Antibody-directed cytotoxic agents: use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells, Proc. Nat'l Acad. Sci. USA 77:4539
100.	Hara et al. (1997) Inhibition of interleukin 1 converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage, Proc Natl Acad Sci USA 94:2007-2012
101.	Hazlehurst et al., 2001, Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells, Blood 96:1897-1903
102.	von Heijne (1985) The leader peptides from bacteriorhodopsin and halorhodopsin are potential membrane-spanning amphipathic helices, J. Mol. Biol. 184: 99-105
103.	Hellstrom et al. (1986) Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas, Proc. Natl. Acad. Sci. USA 83:7059-7063
104.	Hood et al. (2002) Tumor regression by targeted gene delivery to the neovasculature, Science 296, 2404 -2407
105.	Huse et al., (1989) Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda, Science, 246:1275-1281
106.	Karaoglu et al. (1995) Functional characterization of Ost3p. Loss of the 34-kD subunit of the Saccharomyces cerevisiae oligosaccharyltransferase results in biased underglycosylation of acceptor substrates, J. Cell Biol. 130:567-577
107.	Kawakami et al. (2002) Interleukin 4 receptor on human lung cancer: a molecular target for cytotoxin therapy, Clin Cancer Res 8:3503-3511
108.	Knoll et al. (2000) Targeted therapy of experimental renal cell carcinoma with a novel conjugate of monoclonal antibody 138H11 and calicheamicin thetaI1, Cancer Res 60:6089-6094
109.	Koivunen et al. (1994) Isolation of a highly specific ligand for the alpha 5 beta 1 integrin from a phage display library. J. Cell Biol., 124: 373-380
110.	Krolick et al. (1980) Selective killing of normal or neoplastic B cells by antibodies coupled to the A chain of ricin, Proc. Nat'l Acad. Sci. USA 77:5419
111.	Lavaissiere et al (1996) Overexpression of human aspartyl(asparaginyl)beta-hydroxylase in hepatocellular carcinoma and cholangiocarcinoma, J Clin Invest 98(6):1313-23
112.	Lechardeur, et al. (2000) Determinants of the nuclear localization of the heterodimeric DNA fragmentation factor (ICAD/CAD), J Cell Biol 150: 321-334
113.	Lei et al. (1987) Characterization of the Erwinia carotovora pelB gene and its product pectate lyase. J. Bacteriol. 169:4379
114.	Liang et al., 1996, Parallel Synthesis and Screening of a Solid Phase Carbohydrate Library, Science 274:1520-1522
115.	Liu et al. (1996) Eradication of large colon tumor xenografts by targeted delivery of maytansinoids, Proc Natl Acad Sci 93:8618-8623
116.	Loeber et al., 1991, Human NAD(+)-dependent mitochondrial malic enzyme. cDNA cloning. primary structure.

Examiner:	Date Considered:
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. Department of Commerce (Modified) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR §1.98(b))	Attorney Docket No.: ABSALUS-08602	Serial No.: 10/770,668
Applicant: Wright, et al.		
Filing Date: 2/2/2004	Group Art Unit: 1642	

		and expression in <i>Escherichia coli</i> , <i>J. Biol. Chem.</i> 266:3016-3021
	117.	McCafferty et al., 1990, Phage antibodies: filamentous phage displaying antibody variable domains, <i>Nature</i> , 348:552-554
	118.	Ohara et al. (1989) One-Sided Polymerase Chain Reaction: The Amplification of cDNA, <i>PNAS USA</i> 86:5673-5677
	119.	Pai-Scherf et al. (1999) Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor, <i>Clin Cancer Res</i> 5:2311-2315
	120.	Pennington et al. (2001) I κ B kinase-dependent chronic activation of NF- κ B is necessary for p21 ^{WAF/Cip1} inhibition of differentiation-induced apoptosis of monocytes, <i>Mol Cell Biol</i> 21:1930-1941
	121.	Reed, 1997, Double identity for proteins of the Bcl-2 family, <i>Nature</i> 387(6635): 773-776
	122.	Roninson et al. (1986) Isolation of human mdr DNA sequences in multidrug-resistant KB carcinoma cells, <i>Proc Natl Acad Sci</i> 83:4538-4542
	123.	Ross et al. (2002) Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate, <i>Cancer Res</i> 62:2546-2553
	124.	Samejima et al. (1998) Transition from caspase-dependent to caspase-independent mechanisms at the onset of apoptotic execution, <i>J Cell Biol</i> 143:225-239
	125.	Shouval et al (1982) Selecting binding and complement-mediated lysis of human hepatoma cells (PLC/PRF/5) in culture by monoclonal antibodies to hepatitis B surface antigen, <i>Proc Natl Acad Sci, USA</i> 79:650-4
	126.	Suzuki et al. (2002) Possible existence of common internalization mechanisms among arginine-rich peptides, <i>J Biol Chem</i> 277:2437-2443
	127.	Tafari et al. (2000) Cytochrome c-dependent activation of caspase-3 by tumor necrosis factor requires induction of the mitochondrial permeability transition, <i>Am. J. Pathol.</i> 156, 2111-2121
	128.	Tolcher et al. (1999) Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer, <i>J Clin Oncol</i> 17:478-484
	129.	Vivès et al., 1997 A Truncated HIV-1 Tat Protein Basic Domain Rapidly Translocates through the Plasma Membrane and Accumulates in the Cell Nucleus, <i>J Biol Chem</i> 272:16010-16017
	130.	Vuist et al. (1994) Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein, <i>Blood</i> 83:899-906
	131.	Wright et al. (1994) Purification of a 24-kD protease from apoptotic tumor cells that activates DNA fragmentation, <i>J Exp Med.</i> 1994 Dec 1;180(6):2113-23
	132.	Wright et al. (1996) Biochemical pathways of apoptosis: nicotinamide adenine dinucleotide-deficient cells are resistant to tumor necrosis factor or ultraviolet light activation of the 24-kD apoptotic protease and DNA fragmentation. <i>J. Exp. Med.</i> 183: 463-471
	133.	Wright et al. (1997) Activation of CPP32-like proteases is not sufficient to trigger apoptosis: inhibition of apoptosis by agents that suppress activation of AP24, but not CPP32-like activity, <i>J Exp Med.</i> 1997 Oct 6;186(7):1107-17
	134.	Xu et al. (2000) Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2, <i>Clin Cancer Res</i> 6:3334-3341

Examiner:	Date Considered:
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. Department of Commerce (Modified) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR §1.98(b))	Attorney Docket No.: ABSALUS-08602	Serial No.: 10/770,668
Applicant: Wright, et al.		
Filing Date: 2/2/2004		Group Art Unit: 1642

135.	Yang et al., 2001, Preparation and activity of conjugate of monoclonal antibody Hab18 against hepatoma F(ab')(2) fragment and staphylococcal enterotoxin A., World J Gastroenterol. 7:216-221
136.	Youle and Neville (1980) Anti-Thy 1.2 monoclonal antibody linked to ricin is a potent cell-type-specific toxin. Proc. Nat'l Acad. Sci. U.S.A. 77:5483
137.	Akamatsu et al. (1998) A single-chain immunotoxin against carcinoembryonic antigen that suppresses growth of colorectal carcinoma cells, Clin Cancer Res., Nov;4(11):2825-32
138.	Altschul, et al., 1990, Basic local alignment search tool, J. Mol. Biol. 215:403-10 [abstract only]
139.	Balinsky et al., 1984, Enzyme activities in normal, dysplastic, and cancerous human breast tissues, J. Natl. Cancer Inst. 72:217-224 [abstract only]
140.	Bernhard et al., 1983, Guinea pig line 10 hepatocarcinoma model: characterization of monoclonal antibody and in vivo effect of unconjugated antibody and antibody conjugated to diphtheria toxin A chain, Cancer Res 43:4420-4428 [abstract only]
141.	Brody et al, 1999, The use of aptamers in large arrays for molecular diagnostics. Mol Diagn December;4(4):381-8 [abstract only]
142.	Byers et al., 1989, Phase I study of monoclonal antibody-ricin A chain immunotoxin XomaZyme-791 in patients with metastatic colon cancer, Cancer Res 49:6153-6160 [abstract only]
143.	Carloni et al., 1998, Knockout of alpha6 beta1-integrin expression reverses the transformed phenotype of hepatocarcinoma cells, Gastroenterology, Aug;115(2):433-42 [abstract only]
144.	Chan et al, 2001, A humanized monoclonal antibody constructed from intronless expression vectors targets human hepatocellular carcinoma cells, Biochem. Biophys. Res. Commun. 284:157-167 [abstract only]
145.	Chang et al, 1989, Serological analysis and biochemical characterization of monoclonal antibodies defining antigens of human hepatocellular carcinoma, Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi. 1989 Feb;22(1):1-20 [abstract only]
146.	Chou, 1996, Nonidentity of the cDNA sequence of human breast cancer cell malic enzyme to that from the normal human cell, J. Protein Chem. 15:273-279 [abstract only]
147.	Chou et al., 1997, Expression of P-glycoprotein and p53 in advanced hepatocellular carcinoma treated by single agent chemotherapy: clinical correlation, J Gastroenterol Hepatol 12:569-575 [abstract only]
148.	Chou et al., 1999, Solution structure of BID, an intracellular amplifier of apoptotic signaling, Cell, 96: 615-624
149.	Coultas et al., 2003, The role of the Bcl-2 protein family in cancer, Semin Cancer Biol 13:115-123 [abstract only]
150.	Davol et al., 1999, Targeting human prostatic carcinoma through basic fibroblast growth factor receptors in an animal model: characterizing and circumventing mechanisms of tumor resistance, Prostate 40:178-191 [abstract only]
151.	Derossi et al., 1998, Trojan peptides: the penetratin system for intracellular delivery, Trends Cell Biol 8:84-87 [abstract only]
152.	Di Lazzaro et al., 1994, Immunotoxins to the HER-2 oncogene product: functional and ultrastructural analysis of their cytotoxic activity, Cancer Immunol Immunother 39:318-324 [abstract only]
153.	Ding et al., 1995, Synthesis and biological activity of oligosaccharide libraries. Adv. Expt. Med. Biol. 376:261-269 [abstract only]

Examiner:	Date Considered:
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. Department of Commerce (Modified) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR §1.98(b))	Attorney Docket No.: ABSALUS-08602	Serial No.: 10/770,668
	Applicant: Wright, <i>et al.</i>	
	Filing Date: 2/2/2004	Group Art Unit: 1642

154.	Drebin et al., 1988, Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects <i>in vivo</i> , <i>Oncogene</i> 2:387-394 [abstract only]
155.	Dunk et al, 1987, In vitro and in vivo tumour localisation with a monoclonal antibody directed against a membrane antigen on the human hepatocellular carcinoma cell line PLC/PRF/5 <i>J Hepatol</i> 4(1):52-61 [abstract only]
156.	Ecker and Crook, 1995, Combinatorial drug discovery: which methods will produce the greatest value, <i>Biotechnology (N Y)</i> , Apr;13(4):351-60 [abstract only]
157.	Elliot et al., 1997, Intercellular trafficking and protein delivery by a herpesvirus structural protein. <i>Cell</i> 88:223-233 [abstract only]
158.	Enari et al., 1998, A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor, ICAD, <i>Proc. Natl. Acad. Sci.</i> 95:9123-9128 [abstract only]
159.	Ewend et al., 1996, Local delivery of chemotherapy and concurrent external beam radiotherapy prolongs survival in metastatic brain tumor models, <i>Cancer Research</i> 56(22):5217-5223 [abstract only]
160.	Faouzi et al., 1999, Myofibroblasts are responsible for collagen synthesis in the stroma of human hepatocellular carcinoma: an <i>in vivo</i> and <i>in vitro</i> study, <i>J Hepatol</i> 30:275-284 [abstract only]
161.	Fitzgerald et al., 1989, Targeted toxin therapy for the treatment of cancer, <i>J. Nat'l Cancer Inst.</i> 81:1455 [abstract only]
162.	Friede et al., 1994, Selective induction of protection against influenza virus infection in mice by a lipid-peptide conjugate delivered in liposomes, <i>Vaccine</i> , 12:791-797 [abstract only]
163.	Fuhrer et al., 1991, Characterization of a membrane-associated glycoprotein (gp43) on human hepatocellular carcinomas by a monoclonal antibody, <i>Cancer Res.</i> 51:2158-2163 [abstract only]
164.	Fukuda et al., 1988, A monoclonal antibody to the carbohydrate chain on human hepatocellular carcinoma-associated antigen which suppressed tumor growth in nude mice, <i>Cancer Immunol Immunother</i> 27(1):26-32 [abstract only]
165.	Gho et al., 1999, Luteinizing hormone releasing hormone-RNase A conjugates specifically inhibit the proliferation of LHRH-receptor-positive human prostate and breast tumor cells, <i>Mol Cells</i> 9:31-36 [abstract only]
166.	Gao et al., 2003, De novo identification of tumor-specific internalizing human antibody-receptor pairs by phage-display methods, <i>J Immunol Methods</i> 274:185-197 [abstract only]
167.	Giantonio et al., 1997, Superantigen-based immunotherapy: a phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer, <i>J Clin Oncol</i> 15:1994-2007 [abstract only]
168.	Gilbert and Knox, 1997, Influence of Bcl-2 overexpression on Na ⁺ /K ⁺ -ATPase pump activity: correlation with radiation-induced programmed cell death. <i>J Cell Physiol.</i> Jun;171(3):299-304 [abstract only]
169.	Goldstein et al., 1988, Expression of a multidrug resistance gene in human cancers, <i>J Natl Cancer Inst</i> 81:116-124 [abstract only]
170.	Hiraiwa et al. (1990) Accumulation of highly acidic sulfated glycosphingolipids in human hepatocellular carcinoma defined by a series of monoclonal antibodies, <i>Cancer Res</i> 50(10):2917-28
171.	Hiraiwa et al. (1990) Gangliosides and sialoglycoproteins carrying a rare blood group antigen determinant.

Examiner:	Date Considered:
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. Department of Commerce (Modified) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR §1.98(b))	Attorney Docket No.: ABSALUS-08602	Serial No.: 10/770,668
	Applicant: Wright, et al.	
	Filing Date: 2/2/2004	Group Art Unit: 1642

		Cad, associated with human cancers as detected by specific monoclonal antibodies, Cancer Res 50(17):5497-503
	172.	Hu et al., 1986, Monoclonal antibodies against antigens expressed on human hepatocellular carcinoma cells. <u>Hepatology 6(6):1396-402 [abstract only]</u>
	173.	Hu et al, 1999, Cloning and sequencing of variable region genes of HAb25 McAb against hepatocellular carcinoma, <u>Zhonghua Gan Zang Bing Za Zhi.7(2):101-3 [abstract only]</u>
	174.	Huang, 2000, Bcl-2 family proteins as targets for anticancer drug design, <u>Oncogene 19(56): 6627-6631 [abstract only]</u>
	175.	Hwang et al., 1984, Selective antitumor effect on L10 hepatocarcinoma cells of a potent immunoconjugate composed of the A chain of abrin and a monoclonal antibody to a hepatoma-associated antigen, <u>Cancer Res 44:4578-4586 [abstract only]</u>
	176.	Jaattela et al., 1999, Minireview Escaping cell death: Survival proteins in cancer, <u>Exp Cell Res 248:30-43 [abstract only]</u>
	177.	Jaskiewicz et al., 1993, Differential expression of extracellular matrix proteins and integrins in hepatocellular carcinoma and chronic liver disease, <u>Anticancer Res 13:2229-2238 [abstract only]</u>
	178.	Jones et al., 1986, Replacing the complementarity-determining regions in a human antibody with those from a mouse <u>Nature, 321:522 [abstract only]</u>
	179.	Joshi et al., 2002, IL-4 receptors on human medulloblastoma tumours serve as a sensitive target for a circular permuted IL-4-Pseudomonas exotoxin fusion protein, <u>Br J Cancer 86:285-291 [abstract only]</u>
	180.	Kamps et al., 1996, Preparation and characterization of conjugates of (modified) human serum albumin and liposomes: drug carriers with an intrinsic anti-HIV activity, <u>Biochim. Biophys. Acta, 1278:183-190 [abstract only]</u>
	181.	Kawahara et al., 1996 Enhanced coexpression of thioredoxin and high mobility group protein 1 genes in human hepatocellular carcinoma and the possible association with decreased sensitivity to cisplatin. <u>Cancer Res. Dec 1:56(23):5330-3</u>
	182.	Kawai and Hosaki, 1990, Clinical usefulness of malate dehydrogenase and its mitochondrial isoenzyme in comparison with aspartate aminotransferase and its mitochondrial isoenzyme in sera of patients with liver disease, <u>Clin. Biochem. 23:327-334 [abstract only]</u>
	183.	Kuwata et al, 1998, Antibody dependent cell-mediated cytotoxicity using hepatocellular carcinoma reactive monoclonal antibody, <u>J Gastroenterol Hepatol Feb:13(2):137-44 [abstract only]</u>
	184.	Kumagai et al., 1992, A new tumor-associated antigen useful for serodiagnosis of hepatocellular carcinoma, defined by monoclonal antibody KM-2, <u>Cancer Res 52(18):4987-94 [abstract only]</u>
	185.	Lee et al., 1999, Prolonged circulating lives of single-chain Fv proteins conjugated with polyethylene glycol: a comparison of conjugation chemistries and compounds, <u>Bioconjug Chem 10:973-81 [abstract only]</u>
	186.	Li et al., 1998, Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis, <u>Cell, 94: 491-501 [abstract only]</u>
	187.	Lindenboim et al., 2000. Bcl-xS and Bax induce different apoptotic pathways in PC12 cells, <u>Oncogen 19(14): 1783-1793 [abstract only]</u>
	188.	Liu et al., 2001. Inhibition of the growth of hepatoma and hepatic metastasis by pingganmvcin conjugated

Examiner:	Date Considered:
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. Department of Commerce (Modified) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR §1.98(b))	Attorney Docket No.: ABSALUS-08602	Serial No.: 10/770,668
	Applicant: Wright, <i>et al.</i>	
	Filing Date: 2/2/2004	Group Art Unit: 1642

		with Fab' fragment of monoclonal antibody, <i>Zhonghua Yi Xue Za Zhi</i> 81:201-201 [abstract only]
189.	Loh et al. 1989, Polymerase chain reaction with single-sided specificity: analysis of T cell receptor delta chain, <i>Science</i> 243:217-220 [abstract only]	
190.	Luo et al., 1998, Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors, <i>Cell</i> , 94: 481-490 [abstract only]	
191.	Markham et al., 1986, Primary hepatocellular carcinoma localised by a radiolabelled monoclonal antibody, <i>J Hepatol</i> 2(1):25-31 [abstract only]	
192.	Marshall et al., 1997, A biopolymer by any other name would bind as well: a comparison of the ligand-binding pockets of nucleic acids and proteins, <i>Structure</i> , 5: 729-734 [abstract only]	
193.	McDonnell et al., 1999, Solution structure of the proapoptotic molecule BID: a structural basis for apoptotic agonists and antagonists, <i>Cell</i> , 96:625-634 [abstract only]	
194.	Miura et al., 1993, Induction of apoptosis in fibroblasts by IL-1 beta-converting enzyme, a mammalian homolog of the <i>C. elegans</i> cell death gene ced-3, <i>Cell</i> 75:653 [abstract only]	
195.	Moradpour et al., 1995, Specific targeting of human hepatocellular carcinoma cells by immunoliposomes in vitro, <i>Hepatology</i> 22(5):1527-37 [abstract only]	
196.	Morris et al., 2001, A peptide carrier for the delivery of biologically active proteins into mammalian cells. <i>Nature Biotech</i> 19:1173-1176 [abstract only]	
197.	Motte et al. (1989) Characterization of a malignant phenotype-associated cell surface glycoprotein common to various human tumor cells and preferentially expressed on adenocarcinoma of the lung, <i>Cancer Res</i> 49(6): 1349-56 [abstract only]	
198.	Muchi and Yamamoto, 1983, Y Studies on mitochondrial and cytoplasmic malate dehydrogenase in childhood myelodysplastic syndrome, <i>Blood</i> 62:808-814 [abstract only]	
199.	Murray et al, 1993, The expression of cytochrome P-450, epoxide hydrolase, and glutathione S-transferase in hepatocellular carcinoma, <i>Cancer</i> 71:36-43 [abstract only]	
200.	Ng et al., 2000, Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response, <i>Am J Clin Pathol</i> 113:355-363 [abstract only]	
201.	Nishimura et al., 1987, Recombinant human-mouse chimeric monoclonal antibody specific for common acute lymphocytic leukemia antigen. <i>Cancer Res.</i> 1987 Feb 15;47(4):999-1005 [abstract only]	
202.	Ohzu et al, 1990, Multiplicity of newly established monoclonal antibodies against hepatocellular carcinomas, <i>J Gastroenterol Hepatol</i> 5(6):601-7 [abstract only]	
203.	Ozturk et al, 1989, Identification and characterization of a Mr 50,000 adrenal protein in human hepatocellular carcinoma, <i>Cancer Res.</i> 49(23): 6764-73 [abstract only]	
204.	Padlan, 1991, A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties, <i>Molec. Immunol.</i> , 28:489 [abstract only]	
205.	Padlan, 1994, Anatomy of the antibody molecule, <i>Molec. Immunol.</i> , 31(3):169-217 [abstract only]	
206.	Pai et al., 1996, Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to <i>Pseudomonas</i> exotoxin, <i>Nat Med</i> 2:350-353 [abstract only]	
207.	Papsidero, 1985, Recent progress in the immunological monitoring of carcinomas using monoclonal antibodies, <i>Semin. Surg. Oncol.</i> 1(4):171-81 [abstract only]	

Examiner:	Date Considered:
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. Department of Commerce (Modified) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR §1.98(b))	Attorney Docket No.: ABSALUS-08602	Serial No.: 10/770,668
	Applicant: Wright, <i>et al.</i>	
	Filing Date: 2/2/2004	Group Art Unit: 1642

208.	Park et al., 1994, MDR1 gene expression: Its effect on drug resistance to doxorubicin in human hepatocellular carcinoma cell lines, J Natl Cancer Inst 86:700-705 [abstract only]
209.	Patriarca et al., 1993, Patterns of integrin common chain beta 1 and collagen IV immunoreactivity in hepatocellular carcinoma. Correlations with tumour growth rate, grade and size, J Pathol 171:5-11 [abstract only]
210.	Penco et al., 2001, Identification of an import signal for, and the nuclear localization of, human lactoferrin, Biotechnol Appl Biochem 34:151-159 [abstract only]
211.	Reff et al., 2001, A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications, Crit Rev Oncol/Hematol 40:25-35 [abstract only]
212.	Seon et al., 1997, Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Clin Cancer Res 3:1031-1044 [abstract only]
213.	Shahinian et al., 1995, A novel strategy affords high-yield coupling of antibody Fab' fragments to liposomes, Biochim. Biophys. Acta, 1239:157-167 [abstract only]
214.	Shao, 1986, Action of monoclonal antibody against a hepatocellular carcinoma cell line (PLC/PRF/5), Zhonghua Zhong Liu Za Zhi 8(4):259-61 [abstract only]
215.	Shen et al., 1991, Human hepatocellular carcinoma cell lines exhibit multidrug resistance unrelated to MRD1 gene expression, J Cell Sci 98:317-322 [abstract only]
216.	Shimizu et al., 1997, Camptothecin-induced apoptosis in p53-null human leukemia HL60 cells and their isolated nuclei: effects of the protease inhibitors Z-VAD-fmk and dichloroisocoumarin suggest an involvement of both caspases and serine proteases, Leukemia 11:1238-1244 [abstract only]
217.	Shinohara et al., 2000, Site-specific expression of transferrin receptor by human colon cancer cells directly correlates with eradication by antitransferrin recombinant immunotoxin, Int J Oncol 17:643-651 [abstract only]
218.	Shouval et al., 1985, Human hepatoma-associated cell surface antigen: identification and characterization by means of monoclonal antibodies, Hepatology 5(3):347-56 [abstract only]
219.	Siegall et al., 1994, In vitro and in vivo characterization of BR96 sFv-PE40. A single-chain immunotoxin fusion protein that cures human breast carcinoma xenografts in athymic mice and rats, J Immunol 152:2377-2384 [abstract only]
220.	Sjogren et al., 1997, Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats, Cancer Res 57:4530-4536 [abstract only]
221.	Song et al., 1998, Enhanced radioimmunotherapeutic efficacy of a monoclonal antibody cocktail against SMMC-7721 human hepatocellular carcinoma, Cell Res. 8:241-247 [abstract only]
222.	Sordet et al., 1999, Selective inhibition of apoptosis by TPA-induced differentiation of U937 leukemic cells, Cell Death Differ 6:351-361 [abstract only]
223.	Stein et al., 1991, A new murine monoclonal antibody against human hepatoma, Hybridoma 10:255-267 [abstract only]
224.	Stemmer et al., 1995, Single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides, Gene 16:49-53 [abstract only]

Examiner:	Date Considered:
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. Department of Commerce (Modified) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR §1.98(b))	Attorney Docket No.: ABSALUS-08602	Serial No.: 10/770,668
	Applicant: Wright, et al.	
	Filing Date: 2/2/2004	Group Art Unit: 1642

225.	Stennicke and Salvesen, 1999, Caspases: preparation and characterization, Methods. Apr;17(4):313-9 [abstract only]
226.	Takahashi et al, 1989, In vivo expression of two novel tumor associated antigens and their use in immunolocalization of human hepatocellular carcinoma, Hepatology 9(4):625-34 [abstract only]
227.	Takahashi et al., 1988, In vivo localization of human colon adenocarcinoma by monoclonal antibody binding to a highly expressed cell surface antigen, Cancer Res 48(22):6573-9 [abstract only]
228.	Takeuchi et al., 1999, Interferon-alpha modulates resistance to cisplatin in three human hepatoma cell lines, J Gastroenterol 34:351-358 [abstract only]
229.	Tan, 1990, Production of monoclonal antibodies against human hepatocellular carcinoma by immunisation with a cell membrane preparation, Ann Acad. Med. Singapore 19:147-151 [abstract only]
230.	Tanaka et al., 1996, Molecular cloning and mapping of a human cDNA for cytosolic malate dehydrogenase (MDH1) Genomics 32:128-130 [abstract only]
231.	Tannock, 1996, Treatment of cancer with radiation and drugs, Journal of Clinical Oncology 14(12):3156-3174 [abstract only]
232.	Tishler et al., 1992, Taxol: a novel radiation sensitizer, Int J Radiation Oncology and Biological Physics 22(3):613-617 [abstract only]
233.	Torbenson et al., 2002, Hepatocellular carcinomas show abnormal expression of fibronectin protein, Mod Pathol 15:826-830 [abstract only]
234.	Tsung et al, 1980, Derivation and characterization of a monoclonal hybridoma antibody specific for human alpha-fetoprotein. J Immunol Methods 39(4):363-8 [abstract only]
235.	Venook et al., 2000, Hepatocellular carcinoma, Curr Treat Options Oncol. Dec;1(5):407-15 [abstract only]
236.	Verheul et al., 1995, Monopalmitic acid-peptide conjugates induce cytotoxic T cell responses against malarial epitopes: importance of spacer amino acids. J. Immunol. Methods, 182:219-226 [abstract only]
237.	Verhoeyen et al., 1988, Reshaping human antibodies: Grafting an antilysozyme activity Science, 239:1534-1536 [abstract only]
238.	Vitetta et al., 1987, Redesigning nature's poisons to create anti-tumor reagents, Science 238:1098 [abstract only]
239.	Wagenknecht, K. et al. (1988) [Malate dehydrogenase isoenzymes in myocardial infarction] Kardiologia 28:55-57 [abstract only]
240.	Wang et al, 1991, Trichosanthin-monooclonal antibody conjugate specifically cytotoxic to human hepatoma cells in vitro, Cancer Research 51:3353-3355
241.	Wang et al, 1996, BID: a novel BH3 domain-only death agonist. Genes Dev. Nov 15;10(22):2859-69 [abstract only]
242.	Wei et al., 2001, Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death, Science 292(5517): 624-626 [abstract only]
243.	Weidmann et al, 1987, Human hepatocellular carcinoma: cross-reactive and idiotypic antigens associated with malignant transformation of epithelial cells, Hepatology 7(3):543-50 [abstract only]
244.	Wisniewska and Lukasiuk, 1985, [Malate dehydrogenase and its isoenzymes in the peripheral blood leukocytes in progressive muscular dystrophy of the Duchenne type] Neurol. Neurochir. Pol. 19:318-322 [abstract only]

Examiner:	Date Considered:
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. Department of Commerce (Modified) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR §1.98(b))	Attorney Docket No.: ABSALUS-08602	Serial No.: 10/770,668
	Applicant: Wright, et al.	
	Filing Date: 2/2/2004	Group Art Unit: 1642

245.	Wright et al., 1992, Selection of tumor cell variants for resistance to tumor necrosis factor also induces a form of pleiotropic drug resistance, <i>Cancer Immunol Immunother</i> 34:399-406 [abstract only]
246.	Wright et al. (1998) Bcl-2-mediated resistance to apoptosis is associated with glutathione-induced inhibition of AP24 activation of nuclear DNA fragmentation, <i>Cancer Res.</i> 1998 Dec 1;58(23):5570-6
247.	Xie et al., 1998, Characterization of a novel monoclonal antibody raised against human hepatocellular carcinoma, <i>Hybridoma</i> 17:437-444 [abstract only]
248.	Yang et al., 1994, Sequence of light chain variable region gene of a monoclonal antibody to human hepatocarcinoma, <i>Zhonghua Zhong Liu Za Zhi.</i> Jul;16(4):263-5 [abstract only]
249.	Yang et al., 1995, Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death, <i>Cell</i> 80(2):285-291 [abstract only]
250.	Yao et al., 2001, Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody, <i>J Nucl Med</i> 42:1538-1544 [abstract only]
251.	Yoon et al., 2000, Targeting a recombinant adenovirus vector to HCC cells using a bifunctional Fab-antibody conjugate, <i>Biochem Biophys Res Commun</i> 272(2):497-504 [abstract only]
252.	York et al., 1996, The structures of arabinoxyloglucans produced by solanaceous plants. <i>Carbohydr Res.</i> May 14;285:99-128 [abstract only]
253.	Zeng et al, 1993, Radioimmunotherapy for unresectable hepatocellular carcinoma using ¹³¹ I-Hepama-1 mAb: preliminary results, <i>J Cancer Res Clin Oncol</i> 119:257-7 [abstract only]
254.	Zeng et al., 1994, Human anti-(murine Ig) antibody responses in patients with hepatocellular carcinoma receiving intrahepatic arterial ¹³¹ I-labeled Hepama-1 mAb. Preliminary results and discussion. <i>Cancer Immunol Immunother</i> 39:332-336 [abstract only]
255.	Zeng et al., 1998, Improved long-term survival for unresectable hepatocellular carcinoma (HCC) with a combination of surgery and intrahepatic arterial infusion of ¹³¹ I-anti-HCC mAb. Phase I/II clinical trials, <i>J Cancer Res Clin Oncol</i> 124:275-280 [abstract only]
256.	Zhang, et al., 2002, Beta 1-integrin protects hepatoma cells from chemotherapy induced apoptosis via a mitogen-activated protein kinase dependent pathway. <i>Cancer</i> 95:896-906 [abstract only]

Examiner:	Date Considered:
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	